Editorial overview5-HT: The promiscuous and happy hormone!
Section snippets
Professor Nicholas Barnes has been a member of the Faculty of the University of Birmingham Medical School for 21 years and holds the Chair in Neuropharmacology. He is Director of the Cellular and Molecular Neuropharmacology Research Group; the group's principal research interest is 5-HT (5-hydroxytryptamine, serotonin). In addition, Professor Barnes is co-Chairman of the International Union of Basic and Clinical Pharmacology (IUPHAR) Nomenclature Committee for Serotonin Receptors. He is also
References (0)
Cited by (10)
PDZK1/NHERF3 Differentially Regulates Corticotropin-releasing Factor Receptor 1 and Serotonin 2A Receptor Signaling and Endocytosis
2015, Cellular SignallingCitation Excerpt :CRF and 5-HT exert their biological actions by activating a distinct subset of G protein-coupled receptors (GPCRs). CRF binds to the CRF receptors 1 and 2 (CRFR1, 2) and 5-HT binds to the 5-HT receptors 1-7 (5-HT1 -7R), all of which are GPCRs, except for the 5-HT3R, which is a ligand-gated ion channel [8–10]. 5-HT2AR and the CRFR1 represent excellent molecular targets for the treatment of anxiety, eating, and obsessive-compulsive disorders, as well as depression and schizophrenia [11].
Modulation of gut-brain axis by probiotics: A promising anti-depressant approach
2021, Current NeuropharmacologyMediators of inflammation
2018, Immunopharmacology and InflammationPolysaccharide-mediated synthesis of melanins from serotonin and other 5-hydroxy indoles
2018, Future Science OA
Professor Nicholas Barnes has been a member of the Faculty of the University of Birmingham Medical School for 21 years and holds the Chair in Neuropharmacology. He is Director of the Cellular and Molecular Neuropharmacology Research Group; the group's principal research interest is 5-HT (5-hydroxytryptamine, serotonin). In addition, Professor Barnes is co-Chairman of the International Union of Basic and Clinical Pharmacology (IUPHAR) Nomenclature Committee for Serotonin Receptors. He is also Editor-in-Chief, Executive Editor and Associate Editor for the international journals Frontiers in Neuropharmacology, Neuropharmacology, and Frontiers in Neuroscience, respectively.
Professor Barnes is also a member of the working group that advises the UK Government on issues concerning the misuse of drugs and polysubstance abuse.
In addition to his academic-related positions, Professor Barnes is a founder and CEO of Celentyx Ltd.; a pharmaceutical research and development company with a therapeutic focus on immune system disorders.